Brigitte Bressac-de Paillerets

List of Publications by Year in Descending Order

146 papers	11,998 citations	54 h-index	108 g-index
157 ext. papers	13,455 ext. citations	8 avg, IF	5.1 L-index

#	Paper	IF	Citations
146	The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma. *Cancers*, **2021**, 13,	6.6	1
145	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
144	FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells. *Cell Death and Differentiation*, **2021**, 28, 1837-1848	12.7	3
143	Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma. *European Journal of Cancer*, **2021**, 151, 106-114	7.5	2
142	Germline mutation in the NBR1 gene involved in autophagy detected in a family with renal tumors. *Cancer Genetics*, **2021**, 258-259, 51-56	2.3	1
141	Germline mutations in the new E1Pcryptic exon of the gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. *Journal of Medical Genetics*, **2020**, 57, 752-759	5.8	7
140	Melanoma Risk and Melanocyte Biology. *Acta Dermato-Venereologica*, **2020**, 100, adv00139	2.2	6
139	Optimization of Next-Generation Sequencing Technologies for von Hippel Lindau (VHL) Mosaic Mutation Detection and Development of Confirmation Methods. *Journal of Molecular Diagnostics*, **2019**, 21, 462-470	5.1	7
138	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. *The Lancet Child and Adolescent Health*, **2019**, 3, 332-342	14.5	8
137	Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. *Journal of the American Academy of Dermatology*, **2019**, 81, 386-394	4.5	9
136	Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma. *JAMA Dermatology*, **2019**, 155, 604-609	5.1	15
135	Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCT Variants on Cancer Risk. *Molecular Cancer Research*, **2019**, 17, 54-69	6.6	14
134	Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. *Modern Pathology*, **2018**, 31, 874-883	9.8	32
133	Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. *Neuro-Oncology*, **2018**, 20, 1122-1132	1	35
132	Contribution of de novo and mosaic mutations to Li-Fraumeni syndrome. *Journal of Medical Genetics*, **2018**, 55, 173-180	5.8	47
131	Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort. *Nucleic Acids Research*, **2018**, 46, 7913-7923	20.1	37
130	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. *European Journal of Human Genetics*, **2018**, 26, 1732-1742	5.3	23

129	Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. *International Journal of Oncology*, **2018**, 53, 1455-1468	4.4	7
128	Identification of a new exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. *Blood*, **2018**, 132, 469-483	2.2	37
127	Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. *Journal of the National Cancer Institute*, **2018**, 110, 1328-1341	9.7	97
126	GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in and Pathogenic Variant Carriers. *Frontiers in Oncology*, **2018**, 8, 490	5.3	10
125	Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	18
124	Germline /P16INK4A mutations contribute to genetic determinism of sarcoma. *Journal of Medical Genetics*, **2017**, 54, 607-612	5.8	14
123	Occurrence of BAP1 germline mutations in cutaneous melanocytic tumors with loss of BAP1-expression: A pilot study. *Genes Chromosomes and Cancer*, **2017**, 56, 691-694	5	12
122	Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. *Clinical Genetics*, **2017**, 92, 606-615	4	63
121	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
120	Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3. *JAMA Dermatology*, **2017**, 153, 1122-1129	5.1	5
119	Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families. *Journal of Investigative Dermatology*, **2017**, 137, 2606-2612	4.3	10
118	Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk. *European Journal of Human Genetics*, **2016**, 24, 99-105	5.3	14
117	BRCA Share: A Collection of Clinical BRCA Gene Variants. *Human Mutation*, **2016**, 37, 1318-1328	4.7	48
116	The CDKN2A/p16(INK) (4a) 5′UTR sequence and translational regulation: impact of novel variants predisposing to melanoma. *Pigment Cell and Melanoma Research*, **2016**, 29, 210-21	4.5	8
115	Genetic Testing for Melanoma-Where Are We With Moderate-Penetrance Genes?. *JAMA Dermatology*, **2016**, 152, 375-6	5.1	2
114	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. *Journal of Investigative Dermatology*, **2016**, 136, 1066-1069	4.3	9
113	PARKIN Inactivation Links Parkinson's Disease to Melanoma. *Journal of the National Cancer Institute* , **2016**, 108,	9.7	46
112	The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 4764-4768	5.6	12

111	A germline mutation in PBRM1 predisposes to renal cell carcinoma. *Journal of Medical Genetics*, **2015**, 52, 426-30	5.8	24
110	Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome. *Acta Neuropathologica*, **2015**, 129, 921-3	14.3	21
109	Multiple skin hamartomata: a possible novel clinical presentation of SUFU neoplasia syndrome. *Familial Cancer*, **2015**, 14, 151-5	3	10
108	Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. *Science Translational Medicine*, **2015**, 7, 283ra55	17.5	97
107	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
106	Germline BAP1 mutations predispose also to multiple basal cell carcinomas. *Clinical Genetics*, **2015**, 88, 273-7	4	71
105	Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. *Journal of Clinical Oncology*, **2015**, 33, 2345-52	2.2	360
104	The 5Puntranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding. *Oncotarget*, **2015**, 6, 39980-94	3.3	12
103	Diversity of the clinical presentation of the MMR gene biallelic mutations. *Familial Cancer*, **2014**, 13, 131-5	3	15
102	Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. *Nature Genetics*, **2014**, 46, 482-6	36.3	220
101	Relationship between genome and epigenome--challenges and requirements for future research. *BMC Genomics*, **2014**, 15, 487	4.5	21
100	A germline oncogenic MITF mutation and tumor susceptibility. *European Journal of Cell Biology*, **2014**, 93, 71-5	6.1	22
99	Germline mutations of inhibins in early-onset ovarian epithelial tumors. *Human Mutation*, **2014**, 35, 294-7	4.7	11
98	Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. *Cancer Research*, **2014**, 74, 6554-64	10.1	18
97	Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families. *British Journal of Dermatology*, **2013**, 169, 594-9	4	13
96	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
95	Germline BAP1 mutations predispose to renal cell carcinomas. *American Journal of Human Genetics*, **2013**, 92, 974-80	11	188
94	Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. *Pigment Cell and Melanoma Research*, **2013**, 26, 259-62	4.5	62

93	Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests. *Breast Cancer Research and Treatment*, **2013**, 141, 135-44	4.4	31
92	Tracking of second primary melanomas in vemurafenib-treated patients. *JAMA Dermatology*, **2013**, 149, 488-90	5.1	23
91	Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. *Journal of Medical Genetics*, **2013**, 50, 264-70	5.8	89
90	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70
89	Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. *Journal of the American Academy of Dermatology*, **2012**, 67, 1257-64	4.5	21
88	Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. *Human Mutation*, **2012**, 33, 1228-38	4.7	171
87	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. *Nature Genetics*, **2012**, 44, 323-7	36.3	124
86	High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. *Journal of Clinical Oncology*, **2012**, 30, 2087-93	2.2	91
85	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
84	Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. *Haematologica*, **2012**, 97, 9-14	6.6	40
83	Genome-wide association study identifies three new melanoma susceptibility loci. *Nature Genetics*, **2011**, 43, 1108-13	36.3	203
82	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature*, **2011**, 480, 94-8	50.4	365
81	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. *Breast Cancer Research and Treatment*, **2011**, 127, 671-9	4.4	21
80	Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer. *Oncologist*, **2011**, 16, 1250-7	5.7	13
79	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21
78	Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). *Genes and Development*, **2011**, 25, 1245-61	12.6	168
77	Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. *Journal of Medical Genetics*, **2011**, 48, 226-34	5.8	94
76	Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. *Nature Genetics*, **2011**, 43, 1114-8	36.3	126

75	Novel FH mutation in a patient with cutaneous leiomyomatosis associated with cutis verticis gyrata, eruptive collagenoma and Charcot-Marie-Tooth disease. *British Journal of Dermatology*, **2010**, 163, 1337-9	4	6
74	Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro. *European Journal of Endocrinology*, **2010**, 162, 771-7	6.5	25
73	Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. *Journal of the National Cancer Institute*, **2010**, 102, 1568-83	9.7	81
72	Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations. *Journal of Medical Genetics*, **2010**, 47, 142-4	5.8	44
71	Contribution of CDKN2A/P16 (INK4A), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma. *Familial Cancer*, **2010**, 9, 663-7	3	20
70	Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. *Clinical Breast Cancer*, **2010**, 10, 113-8	3	13
69	Characteristics of the coexistence of melanoma and renal cell carcinoma. *Cancer*, **2010**, 116, 5716-24	6.4	15
68	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
67	Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. *Human Mutation*, **2009**, 30, 564-74	4.7	33
66	Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes. *Familial Cancer*, **2009**, 8, 371-7	3	9
65	Genome-wide association study identifies three loci associated with melanoma risk. *Nature Genetics* , **2009**, 41, 920-5	36.3	360
64	2009 version of the Chompret criteria for Li Fraumeni syndrome. *Journal of Clinical Oncology*, **2009**, 27, e108-9; author reply e110	2.2	236
63	Selection criteria for genetic assessment of patients with familial melanoma. *Journal of the American Academy of Dermatology*, **2009**, 61, 677.e1-14	4.5	115
62	The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. *British Journal of Cancer*, **2008**, 99, 364-70	8.7	23
61	Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. *Molecular Oncology*, **2008**, 1, 425-30	7.9	41
60	Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. *Journal of Medical Genetics*, **2008**, 45, 535-8	5.8	155
59	Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN. *Clinical Cancer Research*, **2008**, 14, 5925-30	12.9	54
58	Prise en charge des formes familiales de tumeurs rares : mélanomes familiaux et primitifs multiples. *Oncologie*, **2008**, 10, 411-414	1	

57	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
56	Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. *International Journal of Cancer*, **2007**, 121, 825-31	7.5	39
55	New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment. *Genes Chromosomes and Cancer* , **2007**, 46, 751-60	5	11
54	Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. *British Journal of Cancer*, **2007**, 96, 336-40	8.7	59
53	BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. *Familial Cancer*, **2007**, 6, 453-61	3	31
52	Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. *Journal of Medical Genetics*, **2006**, 43, 39-47	5.8	43
51	High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. *Cancer Research*, **2006**, 66, 9818-28	10.1	313
50	Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours. *British Journal of Cancer*, **2005**, 92, 2278-85	8.7	12
49	Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. *International Journal of Cancer*, **2005**, 117, 230-3	7.5	23
48	Genetic testing in pheochromocytoma or functional paraganglioma. *Journal of Clinical Oncology*, **2005**, 23, 8812-8	2.2	529
47	Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 2384-90	4	59
46	Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. *Journal of the National Cancer Institute*, **2004**, 96, 785-95	9.7	85
45	Significant contribution of germline BRCA2 rearrangements in male breast cancer families. *Cancer Research*, **2004**, 64, 8143-7	10.1	86
44	Soft tissue sarcomas. Case 3. Gastrointestinal stromal tumor and Carney triad. *Journal of Clinical Oncology*, **2004**, 22, 2029-31	2.2	16
43	Is systemic disease in the coelomic epithelium associated with BRCA1 germline mutations?. *Journal of the National Cancer Institute*, **2004**, 96, 488-9	9.7	1
42	Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families. *Clinical Genetics*, **2004**, 65, 131-6	4	41
41	PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. *Gastroenterology*, **2004**, 126, 318-21	13.3	185
40	Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing. *International Journal of Technology Assessment in Health Care*, **2003**, 19, 287-300	1.8	22

39	A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families. *European Journal of Human Genetics*, **2003**, 11, 288-96	5.3	24
38	CDKN2A as a uveal and cutaneous melanoma susceptibility gene. *Genes Chromosomes and Cancer*, **2003**, 38, 265-8	5	28
37	eMelanoBase: an online locus-specific variant database for familial melanoma. *Human Mutation*, **2003**, 21, 2-7	4.7	12
36	Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. *Oncogene*, **2003**, 22, 840-6	9.2	64
35	Localization of a novel melanoma susceptibility locus to 1p22. *American Journal of Human Genetics*, **2003**, 73, 301-13	11	103
34	Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. *Journal of Endocrinology*, **2003**, 178, 301-10	4.7	19
33	BRAF as a melanoma susceptibility candidate gene?. *Cancer Research*, **2003**, 63, 3061-5	10.1	44
32	Hereditary breast cancer associated with a germline BRCA2 mutation in identical female twins with similar disease expression. *Cancer Genetics and Cytogenetics*, **2002**, 133, 24-8		10
31	Testing for BRCA1 mutations: a cost-effectiveness analysis. *European Journal of Human Genetics*, **2002**, 10, 599-606	5.3	46
30	Geographical variation in the penetrance of CDKN2A mutations for melanoma. *Journal of the National Cancer Institute*, **2002**, 94, 894-903	9.7	363
29	The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. *American Journal of Human Genetics*, **2002**, 71, 1395-412	11	109
28	Genetic testing for melanoma. *Lancet Oncology, The*, **2002**, 3, 653-4	21.7	80
27	Genetic and environmental factors in cutaneous malignant melanoma. *Biochimie*, **2002**, 84, 67-74	4.6	38
26	Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma. *Melanoma Research*, **2001**, 11, 117-22	3.3	7
25	Cancer risk in heterozygotes for ataxia-telangiectasia. *International Journal of Cancer*, **2001**, 93, 288-93	7.5	109
24	Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. *Genes Chromosomes and Cancer*, **2001**, 32, 195-202	5	48
23	Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. *British Journal of Cancer*, **2000**, 82, 818-22	8.7	42
22	Extensive molecular screening for hereditary non-polyposis colorectal cancer. *British Journal of Cancer*, **2000**, 82, 871-80	8.7	65

21	Patterns of familial aggregation of three melanoma risk factors: great number of naevi, light phototype and high degree of sun exposure. *International Journal of Epidemiology*, **2000**, 29, 408-415	7.8	14
20	The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations. *American Journal of Human Genetics*, **2000**, 67, 207-212	11	89
19	A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. *American Journal of Human Genetics*, **2000**, 67, 311-9	11	75
18	Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. *British Journal of Cancer*, **1999**, 80, 1042-5	8.7	90
17	Non-Hodgkin's lymphomas and myeloid disorders: deletions associated with t(2;5) and t(3;5) detected by FISH. *Leukemia*, **1998**, 12, 1159-62	10.7	8
16	Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. *Oncogene*, **1998**, 16, 1603-10	9.2	112
15	Absence of somatic alterations of the EB1 gene adenomatous polyposis coli-associated protein in human sporadic colorectal cancers. *British Journal of Cancer*, **1998**, 78, 1356-60	8.7	6
14	p53 STATUS DOES NOT PREDICT INITIAL CLINICAL RESPONSE TO BACILLUS CALMETTE-GUERIN INTRAVESICAL THERAPY IN T1 BLADDER TUMORS. *Journal of Urology*, **1998**, 159, 1079-1084	2.5	39
13	Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. *Human Molecular Genetics*, **1998**, 7, 209-16	5.6	284
12	Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. *Oncogene*, **1997**, 15, 2817-26	9.2	74
11	Genetic transmission of susceptibility to cancer in families of children with soft tissue sarcomas. *Cancer*, **1996**, 78, 1483-91	6.4	16
10	Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. *British Journal of Cancer*, **1996**, 74, 537-45	8.7	83
9	Absence of microsatellite instability in thyroid carcinomas. *European Journal of Cancer*, **1995**, 31A, 128	7.5	11
8	Structure-activity relationships in glucocorticoid-induced apoptosis in T lymphocytes. *Biochemical Pharmacology*, **1995**, 50, 103-10	6	20
7	Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. *European Journal of Immunology*, **1995**, 25, 1638-42	6.1	34
6	Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. *European Journal of Immunology*, **1995**, 25, 1765-9	6.1	81
5	Accumulation of multiple mutations in tumour suppressor genes during colorectal tumorigenesis in HNPCC patients. *Human Molecular Genetics*, **1994**, 3, 2257-60	5.6	92
4	Correlation between p53 gene expression and tumor-cell proliferation in oropharyngeal cancer. *International Journal of Cancer*, **1994**, 57, 458-62	7.5	39

3	Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. *Nature*, **1991**, 350, 429-31	50.4	1185
2	Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 1973-7	11.5	343
1	p53 functions as a cell cycle control protein in osteosarcomas. *Molecular and Cellular Biology*, **1990**, 10, 5772-81	4.8	719